Santen Pharmaceutical CoSNPHY +3.19%82 Pretax Margin % is 23.95% as of Mar. 2026, which is 68% above its 10-year median of 14.24. GuruFocus rates SNPHY with a GF Score™ of 82/100 and a GF Value™ of $10.08 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 73% on this metric.
The historical rank and industry rank for Santen Pharmaceutical Co's Pretax Margin % or its related term are showing as below:
SNPHY'
s Pretax Margin % Range Over the Past 10 Years
Min: -2.08 Med: 14.24 Max: 18.42
Current: 16.27
SNPHY's Pretax Margin % is ranked better than 73% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs SNPHY: 16.27
Santen Pharmaceutical Co (OTCPK:SNPHY) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Santen Pharmaceutical Co Pretax Margin % Related Terms
Santen Pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNPHY vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHY) has a Pretax Margin % of 23.95% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Santen Pharmaceutical Co and its competitors. This is 68% above median its historical median of 14.24. According to the industry distribution chart, Santen Pharmaceutical Co ranks #257 out of 952 companies in the Drug Manufacturers industry, placing it in the top 27%.
Is Santen Pharmaceutical Co's Pretax Margin % too high?
Santen Pharmaceutical Co's current Pretax Margin % of 23.95% is 68% above median its 10-year median of 14.24. The Drug Manufacturers industry median Pretax Margin % is 7.30. Santen Pharmaceutical Co's value of 23.95% is 228.3% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #257 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Santen Pharmaceutical Co has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #257 out of 952 companies for Pretax Margin %. This puts Santen Pharmaceutical Co in the upper half of its industry. The industry median Pretax Margin % is 7.30. Santen Pharmaceutical Co's value of 23.95% is 228.3% above this benchmark. While the company's 10-year median is 14.24 vs. the industry median of 7.30, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current Pretax Margin % of 23.95% is 228.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Santen Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current Pretax Margin % is 23.95%, which is 68% above median its own 10-year median of 14.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.08, compared to a current price of $13.17 — trading 30.7% above its estimated fair value. The current Pretax Margin % is 23.95%, which is 68% above median its 10-year median of 14.24 and 228.3% above the Drug Manufacturers industry median of 7.30. Santen Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current Pretax Margin % is 23.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $13.17 is trading 30.7% above its estimated GF Value™ of $10.08.
GuruFocus considers Santen Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SNPHY:
Pretax Margin %: 23.95% (68% above median its 10-year median of 14.24)
GF Value™: $10.08 vs. price of $13.17 (30.7% above fair value)
Industry Position: 228.3% above the Drug Manufacturers median (#257 of 952)
No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
82GF Score
Get the complete analysis for SNPHY
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHY has been successfully added to your 
